AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections

艾滋病毒及相关感染治疗研究艾滋病临床试验小组

• 批准号: 10812944
• 负责人: Judith S. Currier
• 金额: $ 7622.26万
• 依托单位: UNIVERSITY OF CALIFORNIA LOS ANGELES
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-03 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10812944
• 关键词: 2019-nCoV; AIDS clinical trial group; Accident and Emergency department; Address; Adult; COVID-19 outbreak; COVID-19 pandemic; Cessation of life; Double-blind trial; HIV; Health; Health care facility; Hospitalization; Hospitals; Hour; Immune response; Immunity; Infection; Lead; Medical; Phase; Population; Protocols documentation; Randomized; Research; Risk; SARS-CoV-2 infection; Safety; Therapeutic; acute care; high risk; prevent; primary outcome; severe COVID-19; symptom treatment

Abstract This supplement will support ACTIV-2D ACTIV-2D is a master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with SARS-CoV-2 infection. The protocol is a phase III multicenter, randomized, double blind trial to evaluate the safety and efficacy of S-217622 for the treatment of symptomatic high-risk non-hospitalized adults with SARS-CoV-2 infection. The primary outcome is to determine if the investigational agent (S-217622) will prevent the composite endpoint of hospitalization due to any cause or death due to any cause through study Day 29. Hospitalization is defined as ≥24 hours of acute care, in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe coronavirus disease 2019 (COVID-19) during the COVID-19 pandemic.

抽象的 该补充将支持 ACTIV-2D ACTIV-2D 是评估研究药物治疗以下疾病的安全性和有效性的主方案 该方案是针对患有 SARS-CoV-2 感染的有症状、非住院成人的 III 期多中心研究。 随机、双盲试验，评估 S-217622 治疗症状的安全性和有效性 感染 SARS-CoV-2 的高危非住院成人。 主要结果是确定研究药物 (S-217622) 是否会阻止复合 研究第 29 天因任何原因住院或因任何原因死亡的终点。 住院 定义为在医院或类似的急症护理机构（包括急诊室或 为满足 2019 年严重冠状病毒病患者的医疗需求而设立的临时设施 (COVID-19) 在 COVID-19 大流行期间。

项目成果

PET imaging of bacterial infections with fluorine-18-labeled maltohexaose.

• DOI: 10.1002/anie.201408533
• 发表时间: 2014-12-15
• 期刊: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
• 影响因子: 16.6
• 作者: Ning, Xinghai;Seo, Wonewoo;Lee, Seungjun;Takemiya, Kiyoko;Rafi, Mohammad;Feng, Xuli;Weiss, Daiana;Wang, Xiaojian;Williams, Larry;Camp, Vernon M.;Eugene, Malveaux;Taylor, W. Robert;Goodman, Mark;Murthy, Niren
• 通讯作者: Murthy, Niren

Why cure, why now?

• DOI: 10.1136/medethics-2015-103113
• 发表时间: 2017-02
• 期刊: Journal of medical ethics
• 影响因子: 4.1
• 作者: Kuritzkes DR

Laboratory challenges conducting international clinical research in resource-limited settings.

• DOI: 10.1097/qai.0000000000000038
• 发表时间: 2014-01-01
• 期刊: Journal of acquired immune deficiency syndromes (1999)
• 作者: Fitzgibbon JE;Wallis CL
• 通讯作者: Wallis CL

Marijuana Use Among Young Black Men Who Have Sex With Men and the HIV Care Continuum: Findings From the uConnect Cohort.

• DOI: 10.1080/10826084.2016.1197265
• 发表时间: 2016-11-09
• 期刊: Substance use & misuse
• 影响因子: 2
• 作者: Morgan E;Khanna AS;Skaathun B;Michaels S;Young L;Duvoisin R;Chang M;Voisin D;Cornwell B;Coombs RW;Friedman SR;Schneider JA
• 通讯作者: Schneider JA

Clinical validation of a novel diagnostic HIV-2 total nucleic acid qualitative assay using the Abbott m2000 platform: Implications for complementary HIV-2 nucleic acid testing for the CDC 4th generation HIV diagnostic testing algorithm.

使用 Abbott m2000 平台对新型诊断性 HIV-2 总核酸定性测定进行临床验证：补充 HIV-2 核酸检测对 CDC 第四代 HIV 诊断检测算法的影响。

• DOI: 10.1016/j.jcv.2016.11.011
• 发表时间: 2017
• 期刊: Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
• 作者: Chang,Ming;Wong,AudreyJS;Raugi,DanaN;Smith,RobertA;Seilie,AnnetteM;Ortega,JoseP;Bogusz,KyleM;Sall,Fatima;Ba,Selly;Seydi,Moussa;Gottlieb,GeoffreyS;Coombs,RobertW
• 通讯作者: Coombs,RobertW